GlobeNewswire

Biotech Marketplace ZAGENO Connects All Stakeholders - a 360° Approach

Dela

BOSTON and BERLIN, Jan.  03, 2018  (GLOBE NEWSWIRE) -- ZAGENO Inc. offers a dynamic and industry-leading ecosystem for online ordering in the life science sector. In today's cluttered and nontransparent e-commerce setting, digitally streamlining purchasing processes has become increasingly crucial for all stakeholders. ZAGENO provides useful information for scientists, a decrease in internal costs for procurement departments, and increased reach towards high-potential target audiences for biotechnology vendors.

Life Science Marketplace Connects Major Stakeholders
ZAGENO was founded with the vision to connect scientists, administrative departments, and vendors of biotechnology products through one single platform. ZAGENO enables scientists to order research materials through a comprehensive e-commerce platform comparable to other online shopping websites for consumer products. ZAGENO's co-founders David Pumberger, Florian Wegener, and Kilian Veer established a holistic solution to satisfy all relevant stakeholders. The core of the ZAGENO engine is to fulfill scientists' needs and facilitate their decision-making processes by covering all touchpoints necessary to complete an order online. With the resulting advanced customer experience, ZAGENO laid the foundation for the start-up's accelerated traction with leading life science institutions, academic research environments, and life science research companies.

360° Purchasing Decisions - Bundling Crucial Information
To arrive at well-informed conclusions during the purchasing process is not always easy for scientists. After all, to question the obvious, go the extra mile, and strive for new insights is a personality trait one needs for a successful career in research. To better understand what is crucial for success in this environment, we analyzed scientists' purchasing behavior and brought together three components necessary for a thriving, digital life science marketplace: Content, Community, and Commerce.

Content, Community, and Commerce in Life Science Research
For ZAGENO, content means compiling product specifications from vendors, enabling product comparisons across manufacturers, and enhancing product descriptions and specifications where needed. ZAGENO's expert biotech team curates product details using machine learning software to deliver the best results. Furthermore, a patent-pending "Scientific Score" tells customers how widely used a specific product is and, for example, how many times the product has appeared in peer-reviewed publications.

Globally Accessible High-Value Community Knowledge
Community translates into building a holistic resource for scientists where they can exchange thoughts about products, get support via ZAGENO's unique biotech expert live chat, and access high-quality scientific content available to everyone. Early in 2018, ZAGENO will launch an ISSN-registered peer-review journal (EUREKA! Methods) that will be different from the majority of existing journals in one major respect: access and publishing will be free of charge. This will open opportunities for life science researchers in emerging markets and to scientific and academic institutions that lack adequate funding. With the launch of EUREKA! Methods, the start-up is approaching its next milestone in becoming a global and growing authority in the fields of life science research.

The ZAGENO Ecosystem for Life Science Ordering Online
A new, interconnected biotechnology e-commerce experience is what ZAGENO represents. Every touchpoint combination between scientists, vendors, and procurement needs a thoughtful, specific set-up to work effectively. To optimize, streamline and automate processes, every possible connection was rigorously analyzed, and their resulting scenarios examined. In combination with profound industry insights, the findings helped formulate ZAGENO's dynamic, market-leading set-up. ZAGENO's approach enables smooth, logical integration with all IT systems commonly used in the biotech e-commerce sector and particularly procurement departments. Biotechnology vendors and companies benefit from ZAGENO's online platform by reaching potential customers during their decision-making and buying process. Biotech brands can utilize ZAGENO as an additional digital sales channel to increase their brand's reach in key markets across the USA and Europe, strengthen brand awareness, and promote a positive brand image.

From unconnected stakeholders to integrated biotech industry members
"The entire online process of information gathering, ordering, and order approving within the life science and biotechnology sector is lacking coherence and ease," says Kilian Veer, Chief Operating Officer at ZAGENO Inc. "Maverick ordering is the only method a majority of scientists and laboratories can use to purchase research materials online because there is no other option available helping scientists to make purchasing decisions and streamline administrative order processes," he continues. "With ZAGENO," says Kilian, "we offer an ecosystem to connect all stakeholders via one single platform enabling quick purchasing decisions as well as coherent order information and tracking."

About ZAGENO Inc.
Since its formation in 2015, ZAGENO Inc. has set new standards in the international biotech market. With the vision to offer an online marketplace connecting scientists, academic research institutes, and biotech manufacturers, ZAGENO is growing exponentially and represents a milestone for the digitization of science and research. World-renowned research facilities use ZAGENO for ordering lab equipment and for optimizing internal processes. The start-up employs 47 staff members in Boston (USA) and Berlin (Germany). These two locations were selected for their proximity to renowned institutions known for their research advancements and scientific breakthroughs. For more EUREKA-moments - Welcome to ZAGENO: https://zageno.com

Company Contact:
Gesa Schramme,
VP Digital Growth
ZAGENO Inc.
pr@zageno.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af5e50c1-2fda-4001-8a2e-eb84e7269a0b




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum